Sutro Biopharma Community

NasdaqGM:STRO Community

1 Narratives written by author
0 Comments on narratives written by author
4 Fair Values set on narratives written by author

Sutro Biopharma

AN

AnalystConsensusTarget

Consensus Narrative from 7 Analysts

ADC Pipeline Focus Will Advance Preclinical Drug Development

Key Takeaways Strategic focus on preclinical programs and restructuring is set to drive future growth by enhancing drug development and revenue potential. Workforce reduction and externalization aim to improve margins and extend the cash runway, while partnerships and out-licensing bolster financial flexibility.

US$3.43

FV

82.4% undervalued

-10.01%

Revenue growth p.a.

0

0

3

5 days ago